EW logo

EDWARDS LIFESCIENCES CORP

EWNYSE
πŸ† #299 by market capEarnings Oct 28 Β· PostUS Equity
$87.01β–² $0.18 (+0.21%)
Live
πŸ””
Track EW
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 0.2%
7dβ–Ό 2.0%
14dβ–² 1.5%
30dβ–Ό 3.6%
ytdβ–² 2.1%
1yβ–² 12.7%
🏦Market Cap
$50.10B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+11.6%
Healthy
πŸ“ŠGross Margin
78.0%
High
πŸ’΅FCF Margin
22.0%
Strong
βš–οΈP/S Ratio
7.7x
Fair
Otter Score
56
Weak

Trading Snapshot

Day Range
$86.67 – $88.67
52-Week Range
$72.30 – $96.29
Volume
$4.58B
Avg Volume
$3.19B
Shares Outstanding
575.8M
Next Earnings
Dec 7, 2026

Fundamentals Snapshot

Annual Revenue
$6.07B
Last Q Revenue
$1.74B
P/E Ratio
50.0
P/S Ratio
7.7x
EPS (TTM)
$1.74
Dividend Yield
0.00%
Dilution (1yr)
βˆ’1.5%

Why Investors Own EW

  • βœ“High-growth profile β€” revenue up -8.4% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 45% gross margin and 6% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

EW logo

EDWARDS LIFESCIENCES CORP

EW
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$6.1Bβ–² +11.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
78.1%β–Ό βˆ’1.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$1.6Bβ–² +18.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$1.3Bβ–² +360.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
581.8Mβ–Ό βˆ’1.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2.2Bβ–Ό βˆ’$112M YoY
StockOtter Β· stockotter.space

About EDWARDS LIFESCIENCES CORP

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
56/100

Analyst Price Target

β“˜
Average Target
$103.46
β–² +18.9% Upside
High Target$112.83
Low Target$85.11
Based on 16 analysts

Latest News & Updates

MarketBeatΒ·12d ago

Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead

Edwards Lifesciences NYSE: EW outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian highlighting five therapy areas that the company views as its principal growth platfo

Seeking AlphaΒ·13d ago

Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

GuruFocusΒ·13d ago

EW DCF Analysis: Intrinsic Value $53 vs Price $86

On September 16, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has experienced a mixed price performance recently. The

Business WireΒ·19d ago

Edwards Lifesciences Comments on TAVR National Coverage Decision

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) released by

PRNewsWireΒ·22d ago

Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket p

Business WireΒ·27d ago

Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.Bernard Zovighian, chief executive officer, is scheduled t